Kaehler, Katharina C., Eigentler, Thomas K., Gesierich, Anja, Heinzerling, Lucie, Loquai, Carmen, Meier, Friedegund, Meiss, Frank, Pfoehler, Claudia, Schlaak, Max, Terheyden, Patrick, Thoms, Kai M., Ziemer, Mirjana, Zimmer, Lisa and Gutzmer, Ralf (2018). Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol. Immunother., 67 (5). S. 825 - 835. NEW YORK: SPRINGER. ISSN 1432-0851

Full text not available from this repository.

Abstract

Background Ipilimumab and programmed death (PD) 1-antibodies are effective treatment options in metastatic melanoma. The safety and efficacy of ipilimumab in patients with pre-existing autoimmune disorders (AD) has only been evaluated in a selected number of patients. Methods We performed a retrospective analysis in 14 German skin cancer centers for patients with metastatic melanoma and pre-existing AD treated with ipilimumab. Results 41 patients with 44 pre-existing AD were treated with ipilimumab (thyroiditis n = 15, rheumatoid n = 11, dermatologic n = 10, Crohn's disease/ulcerative colitis n = 3, neurological n = 2, sarcoidosis n = 2, pancreatitis n = 1). 3 out of 41 patients had two AD, 11 patients required immunosuppressants at the time of induction of ipilimumab. 12 patients (29.2%) experienced a flare of their pre-existing AD, mainly patients with rheumatoid or dermatologic diseases. Additional immune-related adverse events (irAEs) occurred in 12 patients (29.2%). In 23 patients (56%) neither a change of their AD nor additional irAEs were observed. Objective responses were seen in five patients (one complete remission, four partial remissions, 12.1%). Conclusion This is the largest series of patients with pre-existing AD and treatment with ipilimumab reported. Flares of pre-existing AD were observed but manageable. Response rates and occurrence of new irAEs were comparable to previous trials. Thus, in this patient subgroup, ipilimumab can be a treatment option after a thorough discussion of pros and cons and taking severity and activity of the preexisting AD into account.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Kaehler, Katharina C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eigentler, Thomas K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gesierich, AnjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heinzerling, LucieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Loquai, CarmenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meier, FriedegundUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Meiss, FrankUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pfoehler, ClaudiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schlaak, MaxUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Terheyden, PatrickUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Thoms, Kai M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ziemer, MirjanaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zimmer, LisaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gutzmer, RalfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-188405
DOI: 10.1007/s00262-018-2134-z
Journal or Publication Title: Cancer Immunol. Immunother.
Volume: 67
Number: 5
Page Range: S. 825 - 835
Date: 2018
Publisher: SPRINGER
Place of Publication: NEW YORK
ISSN: 1432-0851
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ANTI-PD-1 THERAPY; ADVERSE EVENTS; PEMBROLIZUMAB; ASSOCIATION; ANTIGEN-4; DISEASEMultiple languages
Oncology; ImmunologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/18840

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item